Research programme: angiogenesis inhibitors - ProteomTechAlternative Names: Angiogenesis inhibitors research programme - ProteomTech; Antiangiogenesis therapeutics; TL1; TNFSF15; VEGI-192
Latest Information Update: 16 Jul 2016
At a glance
- Originator ProteomTech
- Class Proteins
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer